The authors report the preliminary results of an experience of treatment with clarythromycin in Chlamydia trachomatis endocervicitis/endourethritis; 100% of 51 outpatients treated had negative ELISA results 7-10 days after the end of treatment with clarythromycin 500 mg. b.i.d. for 7 days. Among 64 female outpatients with chlamydial cervicitis treated with erythromycin 1 g b.i.d. for 7 days, 88% were negative at ELISA at the same intervals after therapy. The authors conclude that the efficacy of clarythromycin in this experience makes it use worthy of other and more extensive studies.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
In vitro efficacy of daptomycin and teicoplanin combined with ethanol, clarithromycin or gentamicin as catheter lock solutions.
BMC Microbiol
October 2015
Laboratorio de Investigación Antimicrobiana, Hospital Universitario San Cecilio. Instituto de Investigación Biosanitaria de Granada, 18012, Granada, Spain.
Background: Despite widespread use, optimum choice of antimicrobial agents, concentrations, combinations and exposure times have not been determined for antibiotic lock technique (ALT). Our objective was to evaluate the efficacy of different antibiotic combinations using an in vitro model of catheter-related infection. Daptomycin (DAP) 5 mg/mL, teicoplanin (TEC) 5 mg/mL, both alone and combined with gentamicin (GM) 2.
View Article and Find Full Text PDFThe evolution of Helicobacter pylori antibiotics resistance over 10 years in Greece.
Digestion
September 2015
Academic Department of Gastroenterology, Athens Medical School, 'Laikon' GH, Athens, Greece.
Background: Increasingly, over time, antibiotic resistance is considered a problem for the efficacy of H. pylori eradication treatment. The aim of our study was to evaluate the changes in clarithromycin and levofloxacin resistance of H.
View Article and Find Full Text PDFThe diagnostic sensitivity of the polymerase chain reaction (PCR) and urease respiratory test (URT) in H. pylori infection are compared. The efficacy of H.
View Article and Find Full Text PDF[Clarythromycin in the treatment of exacerbations of chronic obstructive lung disease].
Probl Tuberk Bolezn Legk
October 2006
Clarythromycin (Clerimed) is an antibiotic that has a high antibacterial potential, is successfully used in the treatment of moderate and severe exacerbations of Stage II chronic obstructive lung disease (COLD). Comparison of the clinical efficacy of Clerimed with beta-lactams and respiratory fluoroquinolones has indicated the equal clinical efficacy of the compared groups of drugs. A functional and laboratory monitoring of patients with an exacerbation of COLD treated with Clerimed has established that the most pronounced changes (improvement) occur within the first week of antibiotic therapy, which is typical of control patients.
View Article and Find Full Text PDFRifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin.
Dig Liver Dis
January 2005
Section of Molecular Pathology, Department of Oncology and Neuroscience, G. d'Annunzio University, Chieti-Pescara, Italy.
Background: Rifabutin has been empirically used in Helicobacter pylori infections resistant to triple therapy. There are no data on primary and secondary resistance to rifabutin and its use in specific cases.
Aim: To analyse the susceptibility and resistance to rifabutin in H.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!